“Febuxostat’s Cardiovascular Outcomes in White Male Gout Patients: A Systematic Review of Randomized Controlled Trials Finds Reassuring Results, with Further Studies Needed for Severe Cardiovascular Disease Patients”

https://pubmed.ncbi.nlm.nih.gov/38115182

This systematic review of randomized controlled trials finds that cardiovascular outcomes in majority of White male gout patients treated with febuxostat are reassuring compared to allopurinol, but further studies are needed for patients with severe cardiovascular disease.